| Study period |  | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
 | Enrollment | Allocation | Post-allocation | Close-out | |||||||
 |  |  | Stage 1 | Stage 2 |  | ||||||
TIMEPOINT |  − t1 | 0 | t1 | t2 | t3 | t4 | t5 | t6 | t7 | t8 | t9 |
ENROLLMENT: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Eligibility screen | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Informed Consent | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Allocation | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â |
INTERVENTIONS: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Stage 1 CM | Â | Â | X | X | X | X | Â | Â | Â | Â | Â |
Stage 1 BSM | Â | Â | X | X | X | X | Â | Â | Â | Â | Â |
Stage 2 Switch | Â | Â | Â | Â | Â | Â | X | X | X | X | Â |
Stage 2 Combine | Â | Â | Â | Â | Â | Â | X | X | X | X | Â |
ASSESSMENTS: | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Baseline | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Inclusion/exclusion | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Contact information | X | Â | X | X | X | X | X | X | X | X | Â |
Demographics | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Opioid use disorder | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Outcomes | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Toxicology screen | Â | Â | X | X | X | X | X | X | X | X | X |
Clinic visit attended | Â | Â | X | X | X | X | X | X | X | X | Â |
Moderators | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Opioid Cravings Scale | X | Â | X | X | X | X | X | X | X | X | X |
TAPS Tool Part 1 | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
Timeline Followback | Â | Â | X | X | X | X | X | X | X | X | Â |
Engagement in Substance-free activities | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
PEG for chronic pain | X | Â | X | X | X | X | X | X | X | X | X |
Brief Pain Inventory | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
EQ5D5L | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
PHQ-2 depression | X | Â | X | X | X | X | X | X | X | X | X |
GAD 2 | X | Â | X | X | X | X | X | X | X | X | X |
Delay discounting | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
Opioid Purchase Task | X | Â | X | X | X | X | X | X | X | X | X |
Perceived social support | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | X |
Buprenorphine-naloxone prescribed dose | X | Â | X | X | X | X | X | X | X | X | X |
Buprenorphine-naloxone dose log | Â | Â | X | X | X | X | X | X | X | X | X |